Pharma

Your Article Summary

See Latest Articles

New data from Boehringer Ingelheim's ongoing linagliptin trial programme show promising safety and efficacy results
Boehringer Ingelheim, 06/08/09

Study results presented for the first time in the scientific sessions of this year's American Diabetes Association Annual Meeting show clinically relevant and statistically significant reductions in haemoglobin and fasting plasma glucose levels when linagliptin, a dipeptidyl peptidase 4 inhibitor, is given as add-on therapy in Type 2 diabetic patients inadequately controlled with metformin. Furthermore, these phase II study results show a placebo-like safety and tolerability profile under these therapeutic conditions.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
Repligen, 12/10/09

Fyi from human genome sciences: gsk initiates second pivotal phase 3 trial for investigational cardiovascular medication darapladib
Human Genome Sciences, 12/10/09

Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors
Journal of Clinical Oncology, 12/09/09

 See all of Drug Trials